MARKET

SNSE

SNSE

Sensei Biotherapeutics, Inc.
NASDAQ
0.3564
-0.0064
-1.76%
After Hours: 0.3430 -0.0134 -3.76% 16:57 05/13 EDT
OPEN
0.3628
PREV CLOSE
0.3628
HIGH
0.3746
LOW
0.3431
VOLUME
236.61K
TURNOVER
7.86K
52 WEEK HIGH
1.782
52 WEEK LOW
0.2500
MARKET CAP
8.98M
P/E (TTM)
-0.2969
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SNSE last week (0505-0509)?
Weekly Report · 1d ago
Sensei Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 6d ago
Sensei Biotherapeutics Reports Promising Q1 2025 Results
TipRanks · 6d ago
Sensei Biotherapeutics GAAP EPS of -$0.27
Seeking Alpha · 05/06 15:15
Sensei Biotherapeutics Q1 EPS $(0.27) Misses $(0.22) Estimate
Benzinga · 05/06 13:30
*Sensei Biotherapeutics 1Q Oper Expenses $7.27M >SNSE
Dow Jones · 05/06 11:33
*Sensei Biotherapeutics 1Q Loss $6.86M >SNSE
Dow Jones · 05/06 11:32
*Sensei Biotherapeutics 1Q Loss/Shr 27c >SNSE
Dow Jones · 05/06 11:31
More
About SNSE
More
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
Recently
Symbol
Price
%Change

Webull offers Sensei Biotherapeutics Inc stock information, including NASDAQ: SNSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNSE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNSE stock methods without spending real money on the virtual paper trading platform.